Cargando…

1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort

BACKGROUND: Cabotegravir + rilpivirine (CAB+RPV) injections, the first complete long-acting (LA) antiretroviral therapy (ART) regimen, was approved by the FDA in January 2021 for ART-experienced people with HIV (PWH) who are virologically suppressed (viral load [VL] < 50 copies/mL). We assessed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sension, Michael, Hsu, Ricky K, Fusco, Jennifer S, Brunet, Laurence, Cochran, Quateka, Sridhar, Gayathri, Vannappagari, Vani, van Wyk, Jean A, Wohlfeiler, Michael B, Fusco, Gregory P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678064/
http://dx.doi.org/10.1093/ofid/ofad500.1443
_version_ 1785150277241798656
author Sension, Michael
Hsu, Ricky K
Fusco, Jennifer S
Brunet, Laurence
Cochran, Quateka
Sridhar, Gayathri
Vannappagari, Vani
van Wyk, Jean A
Wohlfeiler, Michael B
Fusco, Gregory P
author_facet Sension, Michael
Hsu, Ricky K
Fusco, Jennifer S
Brunet, Laurence
Cochran, Quateka
Sridhar, Gayathri
Vannappagari, Vani
van Wyk, Jean A
Wohlfeiler, Michael B
Fusco, Gregory P
author_sort Sension, Michael
collection PubMed
description BACKGROUND: Cabotegravir + rilpivirine (CAB+RPV) injections, the first complete long-acting (LA) antiretroviral therapy (ART) regimen, was approved by the FDA in January 2021 for ART-experienced people with HIV (PWH) who are virologically suppressed (viral load [VL] < 50 copies/mL). We assessed the virologic effectiveness of CAB+RPV LA among ART-experienced individuals with VL < 50 copies/mL at initiation in the first 2 years of use in the OPERA® Cohort, stratified by body mass index (BMI). METHODS: All ART-experienced adults with VL< 50 copies/mL at initiation who received ≥ 1 CAB+RPV LA injection for the first time between 21Jan2021 and 28Feb2023 were followed until 25Mar2023. Individuals on either monthly or every 2-month injection schedules were included. Discontinuation was defined as a regimen switch or 2 consecutive missed injections. VLs were monitored from first injection until CAB+RPV discontinuation, death, or study end. Confirmed virologic failure (CVF) was defined as 2 consecutive VLs ≥ 200 copies/mL or 1 VL ≥ 200 copies/mL followed by discontinuation. Results were stratified by BMI at first injection (< 30 vs. ≥ 30 kg/m(2)). RESULTS: All 1843 PWH who received CAB+RPV injections were ART-experienced at start and 1578 (86%) had VL < 50 copies/mL at initiation. Of the 1578 suppressed, 267 (17%) were women, 654 (41%) were Black, 451 (29%) were Hispanic, and 469 (30%) had a BMI of ≥ 30; median age was 40 (IQR: 32, 53) years (Table 1). Among those with CAB+RPV dose available, 1297 (84%) remained on CAB+RPV LA over a median follow-up of 7.4 (IQR: 3.9, 10.9) months at study end. Among 1323 with VLs after first injection, the last VL measured was < 200 copies/mL in 99% (n=1305) and < 50 copies/mL in 94% (n=1237) (Table 2); all follow-up VLs were < 200 copies/mL in 96% (n=1272), and < 50 copies/mL in 84% (n=1115). Regardless of BMI, virologic suppression was maintained by ≥ 98% of individuals and only 1% experienced CVF over follow-up (Table 2). [Figure: see text] [Figure: see text] CONCLUSION: In this real-world cohort of PWH in the United States who received CAB+RPV LA injections, observations from the first 2 years suggest that this regimen is effective among individuals virologically suppressed at initiation. Furthermore, the regimen is consistently effective among those with high BMI. DISCLOSURES: Michael Sension, MD, Gilead: Advisor/Consultant|Gilead: Honoraria|Viiv: Advisor/Consultant|Viiv: Grant/Research Support|Viiv: Honoraria Ricky K. Hsu, MD, Gilead Sciences: Advisor/Consultant|Gilead Sciences: Grant/Research Support|Gilead Sciences: Honoraria|Janssen: Advisor/Consultant|Janssen: Grant/Research Support|Janssen: Honoraria|Merck: Advisor/Consultant|Merck: Honoraria|ViiV Healthcare: Advisor/Consultant|ViiV Healthcare: Honoraria Jennifer S. Fusco, BS, Epividian, Inc.: Salary|Epividian, Inc.: Ownership Interest|Epividian, Inc.: Stocks/Bonds Laurence Brunet, PhD, Epividian, Inc.: Salary|Epividian, Inc.: Stocks/Bonds Gayathri Sridhar, MBBS, MPH, PhD, GlaxoSmithKline: Stocks/Bonds|ViiV Healthcare: Full Time Employee Vani Vannappagari, MBBS, MPH, PhD, GlaxoSmithKline: Stocks/Bonds|ViiV Healthcare: Employee Jean A. van Wyk, MBChB, MFPM, ViiV Healthcare Ltd: Stocks/Bonds Michael B. Wohlfeiler, JD, MD, AAHIVS, ViiV Healthcare: Serves as a PI on clinical trials, but does not receive personal compensation for this work (it goes directly to AIDS Healthcare Foundation) Gregory P. Fusco, MD, MPH, Epividian, Inc.: Board Member|Epividian, Inc.: Ownership Interest|Epividian, Inc.: Stocks/Bonds
format Online
Article
Text
id pubmed-10678064
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106780642023-11-27 1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort Sension, Michael Hsu, Ricky K Fusco, Jennifer S Brunet, Laurence Cochran, Quateka Sridhar, Gayathri Vannappagari, Vani van Wyk, Jean A Wohlfeiler, Michael B Fusco, Gregory P Open Forum Infect Dis Abstract BACKGROUND: Cabotegravir + rilpivirine (CAB+RPV) injections, the first complete long-acting (LA) antiretroviral therapy (ART) regimen, was approved by the FDA in January 2021 for ART-experienced people with HIV (PWH) who are virologically suppressed (viral load [VL] < 50 copies/mL). We assessed the virologic effectiveness of CAB+RPV LA among ART-experienced individuals with VL < 50 copies/mL at initiation in the first 2 years of use in the OPERA® Cohort, stratified by body mass index (BMI). METHODS: All ART-experienced adults with VL< 50 copies/mL at initiation who received ≥ 1 CAB+RPV LA injection for the first time between 21Jan2021 and 28Feb2023 were followed until 25Mar2023. Individuals on either monthly or every 2-month injection schedules were included. Discontinuation was defined as a regimen switch or 2 consecutive missed injections. VLs were monitored from first injection until CAB+RPV discontinuation, death, or study end. Confirmed virologic failure (CVF) was defined as 2 consecutive VLs ≥ 200 copies/mL or 1 VL ≥ 200 copies/mL followed by discontinuation. Results were stratified by BMI at first injection (< 30 vs. ≥ 30 kg/m(2)). RESULTS: All 1843 PWH who received CAB+RPV injections were ART-experienced at start and 1578 (86%) had VL < 50 copies/mL at initiation. Of the 1578 suppressed, 267 (17%) were women, 654 (41%) were Black, 451 (29%) were Hispanic, and 469 (30%) had a BMI of ≥ 30; median age was 40 (IQR: 32, 53) years (Table 1). Among those with CAB+RPV dose available, 1297 (84%) remained on CAB+RPV LA over a median follow-up of 7.4 (IQR: 3.9, 10.9) months at study end. Among 1323 with VLs after first injection, the last VL measured was < 200 copies/mL in 99% (n=1305) and < 50 copies/mL in 94% (n=1237) (Table 2); all follow-up VLs were < 200 copies/mL in 96% (n=1272), and < 50 copies/mL in 84% (n=1115). Regardless of BMI, virologic suppression was maintained by ≥ 98% of individuals and only 1% experienced CVF over follow-up (Table 2). [Figure: see text] [Figure: see text] CONCLUSION: In this real-world cohort of PWH in the United States who received CAB+RPV LA injections, observations from the first 2 years suggest that this regimen is effective among individuals virologically suppressed at initiation. Furthermore, the regimen is consistently effective among those with high BMI. DISCLOSURES: Michael Sension, MD, Gilead: Advisor/Consultant|Gilead: Honoraria|Viiv: Advisor/Consultant|Viiv: Grant/Research Support|Viiv: Honoraria Ricky K. Hsu, MD, Gilead Sciences: Advisor/Consultant|Gilead Sciences: Grant/Research Support|Gilead Sciences: Honoraria|Janssen: Advisor/Consultant|Janssen: Grant/Research Support|Janssen: Honoraria|Merck: Advisor/Consultant|Merck: Honoraria|ViiV Healthcare: Advisor/Consultant|ViiV Healthcare: Honoraria Jennifer S. Fusco, BS, Epividian, Inc.: Salary|Epividian, Inc.: Ownership Interest|Epividian, Inc.: Stocks/Bonds Laurence Brunet, PhD, Epividian, Inc.: Salary|Epividian, Inc.: Stocks/Bonds Gayathri Sridhar, MBBS, MPH, PhD, GlaxoSmithKline: Stocks/Bonds|ViiV Healthcare: Full Time Employee Vani Vannappagari, MBBS, MPH, PhD, GlaxoSmithKline: Stocks/Bonds|ViiV Healthcare: Employee Jean A. van Wyk, MBChB, MFPM, ViiV Healthcare Ltd: Stocks/Bonds Michael B. Wohlfeiler, JD, MD, AAHIVS, ViiV Healthcare: Serves as a PI on clinical trials, but does not receive personal compensation for this work (it goes directly to AIDS Healthcare Foundation) Gregory P. Fusco, MD, MPH, Epividian, Inc.: Board Member|Epividian, Inc.: Ownership Interest|Epividian, Inc.: Stocks/Bonds Oxford University Press 2023-11-27 /pmc/articles/PMC10678064/ http://dx.doi.org/10.1093/ofid/ofad500.1443 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Sension, Michael
Hsu, Ricky K
Fusco, Jennifer S
Brunet, Laurence
Cochran, Quateka
Sridhar, Gayathri
Vannappagari, Vani
van Wyk, Jean A
Wohlfeiler, Michael B
Fusco, Gregory P
1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort
title 1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort
title_full 1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort
title_fullStr 1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort
title_full_unstemmed 1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort
title_short 1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort
title_sort 1608. real-world effectiveness of long-acting cabotegravir + rilpivirine in virologically suppressed treatment-experienced individuals: two years of data from the opera(®) cohort
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678064/
http://dx.doi.org/10.1093/ofid/ofad500.1443
work_keys_str_mv AT sensionmichael 1608realworldeffectivenessoflongactingcabotegravirrilpivirineinvirologicallysuppressedtreatmentexperiencedindividualstwoyearsofdatafromtheoperacohort
AT hsurickyk 1608realworldeffectivenessoflongactingcabotegravirrilpivirineinvirologicallysuppressedtreatmentexperiencedindividualstwoyearsofdatafromtheoperacohort
AT fuscojennifers 1608realworldeffectivenessoflongactingcabotegravirrilpivirineinvirologicallysuppressedtreatmentexperiencedindividualstwoyearsofdatafromtheoperacohort
AT brunetlaurence 1608realworldeffectivenessoflongactingcabotegravirrilpivirineinvirologicallysuppressedtreatmentexperiencedindividualstwoyearsofdatafromtheoperacohort
AT cochranquateka 1608realworldeffectivenessoflongactingcabotegravirrilpivirineinvirologicallysuppressedtreatmentexperiencedindividualstwoyearsofdatafromtheoperacohort
AT sridhargayathri 1608realworldeffectivenessoflongactingcabotegravirrilpivirineinvirologicallysuppressedtreatmentexperiencedindividualstwoyearsofdatafromtheoperacohort
AT vannappagarivani 1608realworldeffectivenessoflongactingcabotegravirrilpivirineinvirologicallysuppressedtreatmentexperiencedindividualstwoyearsofdatafromtheoperacohort
AT vanwykjeana 1608realworldeffectivenessoflongactingcabotegravirrilpivirineinvirologicallysuppressedtreatmentexperiencedindividualstwoyearsofdatafromtheoperacohort
AT wohlfeilermichaelb 1608realworldeffectivenessoflongactingcabotegravirrilpivirineinvirologicallysuppressedtreatmentexperiencedindividualstwoyearsofdatafromtheoperacohort
AT fuscogregoryp 1608realworldeffectivenessoflongactingcabotegravirrilpivirineinvirologicallysuppressedtreatmentexperiencedindividualstwoyearsofdatafromtheoperacohort